Case Type: Mergers & Acquisitions

Luxfer Holdings PLC (NYSE: LXFR) related to its sale to affiliates of Wynnchurch Capital L.P. Under the terms of the proposed transaction, Luxfer shareholders are expected to receive $17.37 per share in cash.

Forte Biosciences, Inc. (NASDAQ: FBRX) related to its sale to argenx BV. Under the terms of the proposed transaction, Forte Biosciences shareholders are expected to receive $77.00 per share in cash.

Safety Insurance Group Inc. (NASDAQ: SAFT) related to its sale to an affiliate of Mapfre S.A. Under the terms of the proposed transaction, Safety Insurance stockholders are expected to receive $105.00 per share in cash.

Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) related to its merger with Scancell Holdings plc. Upon completion of the proposed transaction, Neuphoria stockholders are expected to own 11.1% of the combined company.

Passage Bio, Inc. (NASDAQ: PASG) related to its merger with Remix Therapeutics, Inc.

PBCO Financial Corporation (OTCID: PBCO) related to its merger with Northrim Bancorp, Inc. Under the terms of the proposed transaction, PBCO shareholders are expected to receive 1.160 shares of Northrim common stock for each share of PBCO common stock.

Northrim Bancorp, Inc. (NASDAQ: NRIM) related to its merger with PBCO Financial Corporation.

Novagold Resources Inc. (NYSE American: NG) related to its merger with Donlin Gold LLC.

BioLife Solutions, Inc. (NASDAQ: BLFS) related to its sale to Repligen Corporation. Under the terms of the proposed transaction, BioLife shareholders are expected to receive $11.25 per share in cash and 0.1442 shares of Repligen common stock.

Utz Brands, Inc. (NYSE: UTZ) related to its sale to Intersnack Group GmbH & Co. KG. Under the terms of the proposed transaction, Utz shareholders are expected to receive $14.25 per share in cash.